Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. The company trades on AIM exchange marketplace. The company headquarter is located in United Kingdom. The company was established in the 2017. As of writing, the company status seems to be inactive, which indicates it may not be actively trading on the stock exchanges and may be delisted/merged/suspended/renamed.
TickerVRP
Long NameVerona Pharma PLC
Short NameVerona Pharma
SectorHealthcare
SubsectorBiotechnology
Subsector 2Health Care
CurrencyGBX
ISIN